Analyst Conference Summaries

Biotechnology Investor Aids

Agenus
AGEN

conference date: March 9, 2017 @ 8:00 AM Pacific Time

Incyte Buys Agenus Shares at $6, You Can Buy Them Cheaper [February 15, 2017]

Agenus QS-21 Stimulon part of GSK Malaria Vaccine Gets Positive Review in Europe [July 24, 2015 Agenus press release]

Why Agenus Can Continue to Rise After Doubling [May 15, 2015]

Agenus Platforms Provide Many Shots On Commercialization Goal May 13, 2014 at Seeking Alpha

2016
04/28/2016
07/28/2016
10/27/2016
03/09/2017 
2015
04/23/2015
07/23/2015
10/27/2015
03/03/2016
2014
05/08/2014
07/24/2014
10/31/2014
 02/26/2015
2013
not available
not available 
08/01/2013
10/24/2013
03/05/2014 

Checkpoint Modulators and Combination Therapies for Cancer May 15, 2014 at The Chairman's Blog

Agenus Positive Phase II Glioblastoma (Brain Cancer) Results [July 1 Agenus press release]

Agenus (AGEN) is a development-stage biotechnology company specializing in immunology and cancer therapies including checkpoint modulators (CPMs).

Agenus web site
Agenus investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MDVN
 MYL.
 NVDA
 OPXA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2015 William P. Meyers